doi: 10.1161/hq0102.101821
© 2002 American Heart Association, Inc.
Vascular Biology |
Effects of Dominant-Negative c-Jun on Platelet-Derived Growth Factor–Induced Vascular Smooth Muscle Cell Proliferation
From the Department of Pharmacology, Osaka City University Medical School, Osaka, Japan, and the Gene Experiment Center and Center for Tsukuba Advanced Research Alliance (H.M.), University of Tsukuba, Ibaraki, Japan.
Correspondence to Shokei Kim, MD, Department of Pharmacology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno, Osaka 545-8585, Japan. E-mail kims{at}med.osaka-cu.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Although platelet-derived growth factor (PDGF)-BB is thought to participate in vascular disorders, the mechanism of PDGF-induced vascular smooth muscle cell (SMC) proliferation is not fully understood. This study was undertaken to examine the role of c-Jun in PDGF-BB–induced proliferation of rat aortic SMCs. PDGF-BB (10 ng/mL) significantly increased activator protein (AP)-1 DNA binding activity in SMCs, followed by the increase in [3H]thymidine incorporation and cell number. SMCs were infected with recombinant adenovirus containing TAM67, a dominant-negative c-Jun lacking the transactivation domain of wild c-Jun (Ad-DN-c-Jun), to inhibit endogenous AP-1. Ad-DN-c-Jun, which specifically blocked AP-1 transcriptional activity, significantly inhibited PDGF-BB–induced increases in [3H]thymidine incorporation or cell number. As shown by flow cytometric analysis, Ad-DN-c-Jun inhibited PDGF-BB–induced entrance of SMCs into S phase, leading to a G1 arrest. Ad-DN-c-Jun attenuated PDGF-BB–induced downregulation of p27Kip1, as shown by Western blot analysis, and the prevented PDGF-BB–induced decrease in cyclin E/cyclin-dependent kinase 2 complex–associated p27Kip1, as shown by immunoprecipitation study. Furthermore, protein kinase assay showed that Ad-DN-c-Jun blocked PDGF-BB–induced activation of cyclin-dependent kinase 2. Our results provide the first evidence that dominant-negative c-Jun inhibits PDGF-BB–induced vascular SMC proliferation by preventing the downregulation of p27Kip1, thereby supporting the important role of c-Jun in vascular SMC proliferation.
Key Words: platelet-derived growth factor • smooth muscle cells • c-Jun • gene transfer • proliferation
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Platelet-derived growth factor (PDGF)-BB is known as a multifunctional growth factor capable of stimulating various quiescent cells to proliferate. Accumulating evidence indicates that PDGF-BB is involved in various vascular diseases by stimulating vascular smooth muscle cell (SMC) proliferation, as reviewed.1 However, the mechanism underlying PDGF-induced vascular SMC proliferation is not fully understood. In vascular proliferative diseases, entry into the progression of vascular cells through the cell cycle is thought to be a key event,2 and PDGF-BB, through activation of the ß-PDGF receptor, is a critical mediator of the lesion formation after vascular injury.3 Therefore, detailed investigation into the molecular mechanism underlying PDGF-BB–induced vascular SMC proliferation is essential not only to elucidate the mechanism of vascular diseases but also to develop a new therapeutic strategy for vascular diseases.
The mitogenic action of PDGF-BB is initiated by its interaction with PDGF-BB receptor. Receptor-mediated relocation of cytoplasmic proteins to the inner surface of the plasma membrane, accompanied by subsequent tyrosine phosphorylation, results in the stimulation of multiple signaling pathways, including activation of SHP-2, Src, phospholipase C-
, Ras, protein kinase A, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase, ultimately leading to DNA synthesis, as reviewed.4,5 PDGF also induces the immediate-early gene, including c-jun, c-fos, and c-myc. However, the exact role of these multiple signaling cascades activated by PDGF in SMC proliferation is unclear.
The proto-oncogene c-Jun, known as a component of activator protein (AP)-1, is implicated in the regulation of various gene expressions and of cell proliferation, transformation, differentiation, and apoptosis. It is also clear that the role of c-Jun in cellular responses depends on the cell type and the context of other regulatory influences that the cell is receiving, as reviewed.6 Overexpression of c-Jun is shown to induce apoptosis in 3T3 fibroblasts7 and triggers apoptosis in vascular endothelial cells,8 whereas in cultured fibroblasts and hepatoblasts, c-Jun acts as a positive regulator of cell growth by using c-Jun knockout mice.9–11 However, it remains to be determined whether c-Jun participates in PDGF-BB–induced vascular SMC proliferation. To elucidate the possible contribution of c-Jun to vascular SMC proliferation by PDGF-BB, we constructed a recombinant adenovirus containing the dominant-negative mutant of c-Jun (Ad-DN-c-Jun) and infected rat aortic SMCs with this recombinant adenovirus to inhibit endogenous c-Jun. We obtained the first evidence that c-Jun participates in PDGF-BB–induced vascular SMC proliferation and found a novel mechanism: the downregulation of p27Kip1 by c-Jun is involved in PDGF-BB–induced vascular SMCs proliferation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Reagents and Cells
Human recombinant PDGF-BB was purchased from Sigma Chemical Co. Rat aortic SMCs were prepared from thoracic aortas of male Sprague-Dawley rats (Clea Japan, Tokyo, Japan) by using the collagenase digestion method and cultured as described.12 For all experiments, rat aortic SMCs from passages 4 to 7 were used. SMCs were grown to 70% to 80% confluence and then made quiescent by incubation with DMEM containing 0.1% FBS for 48 hours before the addition of PDGF-BB.
Construction of Ad-DN-c-Jun
The dominant-negative mutant of c-Jun, called TAM67, was generated by removal of the transactivational domain of amino acids 3 to 122 of wild-type c-Jun13 by polymerase chain reaction. TAM67 has the DNA binding domain of wild-type c-Jun. Recombinant replication-defective E1 and E3 adenoviral vectors expressing the TAM67 gene (Ad-DN-c-Jun) were constructed by using an adenovirus expression vector kit (Takara Biomedicals), according to the method of Miyake et al.14 cDNA encoding TAM67 was placed into a cassette cosmid vector, PaxCAwt, which possesses the CAG promoter,15 composed of a cytomegalovirus enhancer, chicken ß-actin promoter, and rabbit ß-globin poly(A) signal. A recombinant adenovirus was constructed by in vitro homologous recombination in 293 cells by using the above cosmid vector, PaxCAwt, containing TAM67 cDNA and the adenovirus DNA-terminal protein complex. Recombinant adenoviruses containing bacterial ß-galactosidase gene (Ad-LacZ) were also constructed as negative controls of Ad-DN-c-Jun, in the same way as Ad-DN-c-Jun. The titer of the virus was determined by limiting dilution in 293 cells and expressed as plaque-forming units.
Adenovirus-Mediated Gene Transfer to SMCs
In vitro gene transfer to aortic SMCs was carried out by incubation with the adenoviral vector with a multiplicity of infection (MOI) of 50, 100, 250, or 500 in DMEM containing 0.1% FBS for 1 hour at 37°C and 5% CO2/95% air. Then, SMCs were made quiescent for 48 hours before being assessed for the expression and the effect of the transferred gene.
An expanded Methods section is available online at http://atvb.ahajournals.org.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Aortic SMC Proliferation and Increase in AP-1 DNA Binding Activity by PDGF-BB
As estimated by [3H]thymidine incorporation, treatment of aortic SMCs with PDGF-BB for 24 hours increased the rate of DNA synthesis in a dose-dependent manner, and 10 ng/mL of PDGF-BB exerted an almost maximal effect (see online Figure I-A,, which can be accessed at http://atvb.ahajournals.org). Therefore, PDGF-BB stimulation of SMCs was carried out at a dose of 10 ng/mL in all experiments, except for the experiment of dose response. The addition of 10 ng/mL PDGF-BB significantly increased SMC numbers with time (see online Figure I-B), preceded by a 7.8-fold increase in AP-1 DNA binding activity at 2 hours (see online Figure I-C).
Ad-DN-c-Jun Specifically Increases AP-1 DNA Binding and Blocks AP-1 Transcriptional Activity
In preliminary experiments, we examined the transgene expression of ß-galactosidase in SMCs infected with Ad-LacZ at an MOI of 50, 100, 250, or 500 by using in situ ß-galactosidase staining and found that the transgene expression of ß-galactosidase in SMCs reached a plateau with the adenoviral infection at 250 MOI (data not shown). Furthermore, we examined the effects of Ad-DN-c-Jun on PDGF-BB–induced aortic SMC proliferation at the above-mentioned MOI and found that Ad-DN-c-Jun at 250 MOI significantly inhibited aortic SMC proliferation, whereas Ad-LacZ at the same MOI did not inhibit proliferation at all. Therefore, in all experiments, we compared the effects of Ad-DN-c-Jun with those of Ad-LacZ at 250 MOI. Aortic SMCs infected with Ad-DN-c-Jun at 250 or 500 MOI expressed significant amounts of DN-c-Jun mRNA (see online Figure II-A, which can be accessed at http://atvb.ahajournals.org) and protein (see online Figure II-B), indicating successful DN-c-Jun gene transfer with adenoviruses. As indicated by gel mobility shift analysis in Figure 1A, Ad-DN-c-Jun infection increased AP-1 DNA binding activity. However, the position of the AP-1 band that was due to Ad-DN-c-Jun was higher than that of the PDGF-BB–induced endogenous AP-1 band. Ad-Lac Z did not affect AP-1 DNA binding activity with or without PDGF-BB. As shown by supershift analysis in Figure 1B, PDGF-BB–induced AP-1 was supershifted with the anti–c-Jun antibody recognizing the transactivation domain of wild-type c-Jun (sc-822X), the anti–c-Jun antibody recognizing the conserved DNA binding domain (sc-44X), or the anti–c-Fos antibody. On the other hand, the Ad-DN-c-Jun–induced AP-1 band was supershifted only with the anti–c-Jun antibody recognizing the conserved DNA binding domain, ie, sc-44X, but not with the anti–c-Jun antibody sc-822X or anti–c-Fos antibody (Figure 1B). To confirm the specificity of this increased AP-1 activity that was due to Ad-DN-c-Jun, we examined the serum response element (SRE), nuclear factor (NF)-
B, and stimulatory protein-1 (Sp1) DNA binding activity. Figure 2 shows that Ad-DN-c-Jun infection did not affect the SRE, NF-B, and Sp1 DNA binding activity. Moreover, as shown by dual luciferase assay in Figure 3, PDGF-BB increased AP-1 transcriptional activity in aortic SMCs, and this increase was significantly inhibited by Ad-DN-c-Jun but not by Ad-Lac Z. Furthermore, Ad-DN-c-Jun infection did not change SRE and NF-B transcriptional activity, indicating specific blockade of AP-1 transcriptional activity by Ad-DN-c-Jun.
|
|
|
Ad-DN-c-Jun Attenuates PDGF-BB–Induced Proliferation Through G1 Arrest
Infection of aortic SMCs with Ad-DN-c-Jun at 250 MOI diminished the PDGF-BB–induced increase in [3H]thymidine incorporation by 42%, whereas Ad-LacZ had no effect (Figure 4A). Ad-DN-c-Jun or Ad-LacZ did not affect [3H]thymidine incorporation in SMCs without PDGF-BB stimulation. Ad-DN-c-Jun also inhibited the PDGF-BB–induced increase in cell number by 38% (Figure 4B), whereas this increase was not affected by Ad-LacZ, even at 500 MOI (Figure 4B). Neither adenoviral infection affected the SMC number without PDGF-BB stimulation (data not shown). Flow cytometric analysis showed that Ad-DN-c-Jun significantly inhibited PDGF-BB–induced S-phase entrance of SMCs and increased the percentage of SMCs in G0/G1 phase, whereas Ad-LacZ did not significantly affect it (Figure 5).
|
|
Effects of DN-c-Jun on p27Kip1, p21Cip1, p53, and Cyclin-Dependent Kinase 2 Activity
As shown in Figure 6A, PDGF-BB exposure of aortic SMCs downregulated p27Kip1 in a time-dependent manner, which is consistent with the findings by Servant et al.16 On the other hand, PDGF-BB increased p21Cip1 in a time-dependent manner and did not change p53 levels.
|
-tubulin antibody. Each value represents mean±SEM. *P<0.05 vs PDGF-BB (-). The experiments were repeated 3 times, and similar results were obtained. C, Detergent lysates of aortic SMCs with or without prior adenovirus infection, exposed to PDGF-BB (10 ng/mL, 16 hours) or not, were subjected to immunoprecipitation (IP) with anti–cyclin E antibody or anti-p27Kip1 antibody and analyzed by Western blotting with either antibody. The experiments were repeated 3 times, and similar results were obtained. D, The phosphotransferase activity of Cdk2 was determined by protein kinase assay, immunoprecipitating with Cdk2 antibody, and using histone H1 as substrate, as described in detail in experimental procedures. The experiments were repeated twice, and similar results were obtained. E, Western blot analysis was performed with antibodies to p27Kip1, p21Cip1, and p53. The experiments were repeated twice, and similar results were obtained.As shown in Figure 6B, this downregulation of p27Kip1 in SMCs exposed to PDGF-BB (16 hours) was prevented by Ad-DN-c-Jun (250 MOI) by 62% but not by Ad-LacZ. In SMCs not subjected to PDGF-BB stimulation, neither Ad-LacZ nor Ad-DN-c-Jun significantly affected p27Kip1.
p27Kip1 is known to inhibit the cyclin-regulatory subunit and catalytic cyclin-dependent kinase (Cdk) complex activity, including cyclin E/Cdk2 activity. Cyclin E/Cdk2 activity is essential for entry into S phase.17,18 To further elucidate the molecular mechanism of PDGF-BB–induced SMC proliferation, an immunoprecipitation study with anti–cyclin E antibody or anti-p27Kip1 antibody was performed to determine cyclin E–associated p27Kip1 levels. As shown in Figure 6C, the addition of PDGF-BB (10 ng/mL, 16 hours) significantly decreased cyclin E–associated p27Kip1 levels, which is in good agreement with the results of Servant et al.16 Compared with Ad-LacZ, Ad-DN-c-Jun infection significantly prevented the PDGF-BB–induced decrease in cyclin E–associated p27Kip1.
Furthermore, Cdk2 activity was measured by the immune complex kinase assay by using histone H1 as a substrate. As shown in Figure 6D, treatment of aortic SMCs with PDGF-BB (10 ng/mL, 16 hours) activated Cdk2, and this activation was significantly blocked by Ad-DN-c-Jun but not by Ad-Lac Z. Neither adenoviral infection affected the Cdk2 activity in aortic SMCs not subjected to PDGF-BB treatment.
As shown in Figure 6E, Ad-DN-c-Jun did not affect p21Cip1 or p53 levels in SMCs with or without PDGF-BB (16 hours). In addition, we examined the effects of Ad-DN-c-Jun on the protein expression of cyclin D1, cyclin E, Cdk2, and Cdk4. Compared with Ad-LacZ, Ad-DN-c-Jun did not prevent an increase in cyclin D1, cyclin E, Cdk2, or Cdk4 proteins by PDGF-BB (data not shown).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Accumulating evidence supports the notion that PDGF is involved in a variety of vascular diseases by stimulating vascular SMC proliferation, as reviewed.1 We and other groups of investigators have shown that tyrosine phosphorylation of the PDGF receptor, particularly the PDGF ß-receptor activated by PDGF-BB, is enhanced in balloon-injured arteries, hypertensive aortas, and other vascular lesions.19,20 Vascular SMC proliferation by PDGF in vitro is mediated by multiple intracellular signaling molecules, such as Ras, protein kinase C, Src, or phosphatidylinositol 3-kinase, as reviewed.5 In the present study, using an adenoviral expression vector containing TAM67 (a dominant-negative c-Jun gene), we investigated the novel mechanism responsible for PDGF-BB–induced vascular SMC proliferation and obtained the first evidence that c-Jun partially but significantly contributes to PDGF-BB–induced vascular SMC proliferation through the downregulation of p27Kip1, the activation of Cdk2, and the subsequent induction of G1/S transition.
As recently reviewed,6 c-Jun exerts diverse biological functions, including cell proliferation, transformation, differentiation, and apoptosis, depending on the cell type and the context of other regulatory influences that the cell is receiving. c-Jun plays a critical role in the proliferation of cultured fibroblasts and hepatoblasts,9–11 whereas c-Jun overexpression is shown to induce apoptosis in 3T3 fibroblasts7 and trigger apoptosis in vascular endothelial cells.8 However, the biological role of c-Jun in vascular SMCs remains to be determined. We have previously reported that AP-1 binding activity, composed of c-Jun, is significantly enhanced in injured rat artery by balloon angioplasty21 and angiotensin II–mediated hypertension,22 suggesting that c-Jun may play some role in various vascular diseases. These findings encouraged us to elucidate the role of c-Jun in PDGF-BB–induced vascular SMC proliferation. The use of adenoviruses containing the dominant-negative c-Jun gene allowed us to specifically suppress endogenous c-Jun. To our knowledge, the present work provides the first evidence that c-Jun participates in PDGF-BB–induced vascular SMC proliferation. Furthermore, our recent work,23 in which we used a dominant-negative mutant of extracellular signal–regulated kinase (ERK) or c-Jun amino-terminal kinase (JNK), indicates that ERK and JNK are involved in vascular SMC proliferation. Taken together with the fact that these kinases can activate AP-1,24 these findings suggest that c-Jun may participate in ERK- or JNK-induced SMC proliferation.
The progression that exit cells from G1 phase into S phase is regulated by the activation of multiple holoenzymes composed of cyclin-regulatory subunit and catalytic Cdk.2 Particularly, cyclin E/Cdk2 activity is essential for entry into S phase.17,18,25 Cyclin-dependent kinase inhibitor (CKI) p27Kip1 has been initially characterized as an inhibitor of cyclin E/Cdk2 activation that is responsible for retinoblastoma gene product phosphorylation.26,27 Ectopic expression of p27Kip1 causes cell cycle arrest in G1 phase,26 and conversely, antisense inhibition of p27Kip1 expression suppresses quiescence in fibroblasts.28,29 The expression of p27Kip1 is increased in serum-starved or density-arrested cells and in cells exposed to antiproliferative signals, such as transforming growth factor-ß1.30–32 In contrast, p27Kip1 levels decline in response to mitogenic factors,28,31,33 and overexpression of p27Kip1 cDNA in vascular SMCs inhibits mitogen-stimulated [3H]thymidine incorporation.34 Importantly, downregulation of p27Kip1 during late G1 phase plays an important role in cell cycle progression from G1 to S phase.28,32 Recently, Servant et al16 reported that PDGF-BB downregulates p27Kip1 and then enhances Cdk2 activity in the late G1 phase of mitogenic response in vascular SMCs, whereas in angiotensin II–induced hypertrophic response, neither enhanced Cdk2 activity nor downregulation of p27Kip1 is found, showing that the downregulation of p27Kip1 is important in vascular SMC proliferation. However, the mechanism responsible for the downregulation of p27Kip1 by PDGF-BB remains to be determined. Therefore, in the present study, we investigated the role of c-Jun in PDGF-BB–induced downregulation of p27Kip1 in vascular SMCs. Our present results showed that Ad-DN-c-Jun infection of vascular SMCs prevented PDGF-BB–induced p27Kip1 downregulation (Figure 6B) and inhibited a PDGF-BB–induced decrease in cyclin-E/Cdk2 complex–associated p27Kip1 (Figure 6C), leading to the blockade of Cdk2 activation (Figure 6D) and the subsequent cell cycle arrest in G1 phase (Figure 5). Thus, the present work provided the first evidence that there is a link between c-Jun and p27Kip1 in the regulation of mitogenic cell progression and that c-Jun–dependent p27Kip1 downregulation participates in PDGF-induced proliferation of vascular SMCs.
Although the Kip/Cip family of CKIs, including p27Kip1 and p21Cip1, are thought to be negative regulators of the cyclin/Cdk complex, there have been some reports indicating that the CKIs positively regulate cyclin/Cdk activation.31,32,35,36 Recently, CKI p21Cip1 has been reported to exhibit permissive effects on PDGF-BB–induced vascular SMC cycle progression, as shown by the fact that transfection of several lines of vascular SMCs with p21Cip1 antisense decreased the association of cyclin D1/Cdk4 but not cyclin E/Cdk2 and resulted in the inhibition of PDGF-BB–induced proliferation.37 In the present study, we found that PDGF-BB increased p21Cip1 in a time-dependent manner within 24 hours, which is in good agreement with the previous report.37 However, Ad-DN-c-Jun infection of aortic SMCs did not significantly affect the PDGF-BB–induced increase in p21Cip1 (Figure 6D), thereby providing no evidence for the involvement of p21Cip1 in c-Jun–dependent vascular SMC proliferation by PDGF-BB.
Previous reports have shown that c-Jun–mediated cell proliferation is associated with p53 in mouse embryo fibroblasts38 and with cyclin D1 in NIH 3T3 mouse fibroblasts.39 Nevertheless, in vascular SMCs, the present study showed no effect of PDGF-BB on p53 protein levels (Figure 6A) and no alteration of p53 levels by Ad-DN-c-Jun (Figure 6D), providing no evidence for the important role of p53 in c-Jun–dependent SMC proliferation by PDGF-BB. In the present study, we also examined whether the regulation of cyclin D1, cyclin E, Cdk2, and Cdk4 protein levels is involved in this c-Jun–mediated proliferation and found no contribution of c-Jun to the PDGF-BB–induced increase in these protein levels. Thus, in vascular SMCs, p27Kip1 seems to specifically play a pivotal role in c-Jun–dependent G1/S transition and proliferation induced by PDGF-BB.
The present study did not allow us to elucidate the inhibitory mechanism of PDGF-induced p27Kip1 downregulation by DN-c-Jun. Generally, p27Kip1 levels are controlled by various mechanisms, including (1) posttranscriptional mechanisms, such as the ubiquitin-proteasome pathway and the ubiquitin-independent processing pathway,40 (2) the transcriptional mechanism,16 and (3) the phosphorylation of p27Kip1 by activated cyclin E/Cdk2.41 However, further study is needed to elucidate which mechanism(s) participates in the inhibition of PDGF-induced p27Kip1 downregulation by DN-c-Jun.
In conclusion, c-Jun plays a pivotal role in PDGF-BB–induced vascular SMC proliferation, which is mediated by CKI p27Kip1. Our work provides not only a new insight into the molecular mechanism underlying PDGF-induced vascular SMC proliferation but also a new therapeutic approach for targeting the cell cycle in proliferative vascular diseases.
|
Acknowledgments |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study was supported in part by the Sasagawa Medical Scholarship of the Japan-Sino Medical Association, the Soroptimist Scholarship of Japan Chuo Region of Soroptimist International of the Americas, Inc, and the Hoh-ansha Foundation.
Received June 6, 2001; accepted October 16, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999; 79: 1283–1316.
2.
Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998; 98: 82–89.
3.
Giese NA, Marijianowski MM, McCook O, Hancock A, Ramakrishnan V, Fretto LJ, Chen C, Kelly AB, Koziol JA, Wilcox JN, et al. The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. Arterioscler Thromb Vasc Biol. 1999; 19: 900–909.
4.
Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem. 1994; 269: 32023–32026.
5. Heldin CH. Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS Lett. 1997; 410: 17–21.[CrossRef][Medline] [Order article via Infotrieve]
6. Leppa S, Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene. 1999; 18: 6158–6162.[CrossRef][Medline] [Order article via Infotrieve]
7. Bossy-Wetzel E, Bakiri L, Yaniv M. Induction of apoptosis by the transcription factor c-Jun. EMBO J. 1997; 16: 1695–1709.[CrossRef][Medline] [Order article via Infotrieve]
8.
Wang N, Verna L, Hardy S, Zhu Y, Ma KS, Birrer MJ, Stemerman MB. c-Jun triggers apoptosis in human vascular endothelial cells. Circ Res. 1999; 85: 387–393.
9.
Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev. 1993; 7: 1309–1317.
10. Hilberg F, Aguzzi A, Howells N, Wagner EF. c-Jun is essential for normal mouse development and hepatogenesis. Nature. 1993; 365: 179–181.[CrossRef][Medline] [Order article via Infotrieve]
11.
Eferl R, Sibilia M, Hilberg F, Fuchsbichler A, Kufferath I, Guertl B, Zenz R, Wagner EF, Zatloukal K. Functions of c-Jun in liver and heart development. J Cell Biol. 1999; 145: 1049–1061.
12.
Hamaguchi A, Kim S, Izumi Y, Zhan Y, Yamanaka S, Iwao H. Contribution of extracellular signal–regulated kinase to angiotensin II–induced transforming growth factor-beta1 expression in vascular smooth muscle cells. Hypertension. 1999; 34: 126–131.
13. Brown PH, Chen TK, Birrer MJ. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene. 1994; 9: 791–799.[Medline] [Order article via Infotrieve]
14.
Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A. 1996; 93: 1320–1324.
15. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108: 193–199.[CrossRef][Medline] [Order article via Infotrieve]
16.
Servant MJ, Coulombe P, Turgeon B, Meloche S. Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol. 2000; 148: 543–556.
17. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 1995; 15: 2612–2624.[Abstract]
18.
van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 1993; 262: 2050–2054.
19.
Abe J, Deguchi J, Matsumoto T, Takuwa N, Noda M, Ohno M, Makuuchi M, Kurokawa K, Takuwa Y. Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: a link between angiotensin II and intimal thickening. Circulation. 1997; 96: 1906–1913.
20.
Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol. 2000; 20: 2539–2545.
21.
Kim S, Izumi Y, Yano M, Hamaguchi A, Miura K, Yamanaka S, Miyazaki H, Iwao H. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation. 1998; 97: 1731–1737.
22.
Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II–mediated hypertension. Circ Res. 1998; 83: 752–760.
23.
Izumi Y, Kim S, Namba M, Yasumoto H, Miyazaki H, Hoshiga M, Kaneda Y, Morishita R, Zhan Y, Iwao H. Gene transfer of dominant-negative mutants of extracellular signal–regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res. 2001; 88: 1120–1126.
24.
Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001; 81: 807–869.
25. Knoblich JA, Sauer K, Jones L, Richardson H, Saint R, Lehner CF. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell. 1994; 77: 107–120.[CrossRef][Medline] [Order article via Infotrieve]
26. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994; 78: 67–74.[CrossRef][Medline] [Order article via Infotrieve]
27. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994; 78: 59–66.[CrossRef][Medline] [Order article via Infotrieve]
28. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996; 272: 877–880.[Abstract]
29.
Rivard N, L’Allemain G, Bartek J, Pouyssegur J. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem. 1996; 271: 18337–18341.
30.
Firpo EJ, Koff A, Solomon MJ, Roberts JM. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol. 1994; 14: 4889–4901.
31. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 1994; 79: 487–496.[CrossRef][Medline] [Order article via Infotrieve]
32. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994; 372: 570–573.[CrossRef][Medline] [Order article via Infotrieve]
33.
Winston J, Dong F, Pledger WJ. Differential modulation of G1 cyclins and the Cdk inhibitor p27 kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. J Biol Chem. 1996; 271: 11253–11260.
34. Braun-Dullaeus RC, Mann MJ, Ziegler A, von der Leyen HE, Dzau VJ. A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest. 1999; 104: 815–823.[Medline] [Order article via Infotrieve]
35.
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995; 269: 682–685.
36. Resnitzky D, Hengst L, Reed SI. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol. 1995; 15: 4347–4352.[Abstract]
37.
Weiss RH, Joo A, Randour C. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem. 2000; 275: 10285–10290.
38.
Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999; 13: 607–619.
39. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000; 19: 2056–2068.[CrossRef][Medline] [Order article via Infotrieve]
40.
Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, Nakayama K, Kitagawa M. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem. 1999; 274: 13886–13893.
41.
Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997; 11: 1464–1478.
This article has been cited by other articles:
 |
|
 |
|
  J. W. Gordon, C. Pagiatakis, J. Salma, M. Du, J. J. Andreucci, J. Zhao, G. Hou, R. L. Perry, Q. Dan, D. Courtman, et al. Protein Kinase A-regulated Assembly of a MEF2{middle dot}HDAC4 Repressor Complex Controls c-Jun Expression in Vascular Smooth Muscle Cells J. Biol. Chem., July 10, 2009; 284(28): 19027 - 19042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Shen, I. P. Uray, Y. Li, Y. Zhang, J. Hill, X.-C. Xu, M. R. Young, E. J. Gunther, S. G. Hilsenbeck, N. H. Colburn, et al. Targeting the Activator Protein 1 Transcription Factor for the Prevention of Estrogen Receptor-Negative Mammary Tumors Cancer Prevention Research, June 1, 2008; 1(1): 45 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Izumi, S. Kim, M. Yoshiyama, Y. Izumiya, K. Yoshida, A. Matsuzawa, H. Koyama, Y. Nishizawa, H. Ichijo, J. Yoshikawa, et al. Activation of Apoptosis Signal-Regulating Kinase 1 in Injured Artery and Its Critical Role in Neointimal Hyperplasia Circulation, December 2, 2003; 108(22): 2812 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamada, S. Kim, K. Egashira, M. Takeya, T. Ikeda, O. Mimura, and H. Iwao Molecular Mechanism and Role of Endothelial Monocyte Chemoattractant Protein-1 Induction by Vascular Endothelial Growth Factor Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 1996 - 2001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Monje, M. J. Marinissen, and J. S. Gutkind Phosphorylation of the Carboxyl-Terminal Transactivation Domain of c-Fos by Extracellular Signal-Regulated Kinase Mediates the Transcriptional Activation of AP-1 and Cellular Transformation Induced by Platelet-Derived Growth Factor Mol. Cell. Biol., October 1, 2003; 23(19): 7030 - 7043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhan, S. Kim, Y. Izumi, Y. Izumiya, T. Nakao, H. Miyazaki, and H. Iwao Role of JNK, p38, and ERK in Platelet-Derived Growth Factor-Induced Vascular Proliferation, Migration, and Gene Expression Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Schulze, G. W. De Keulenaer, J. Yoshioka, K. A. Kassik, and R. T. Lee Vitamin D3-Upregulated Protein-1 (VDUP-1) Regulates Redox-Dependent Vascular Smooth Muscle Cell Proliferation Through Interaction With Thioredoxin Circ. Res., October 18, 2002; 91(8): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||